Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan

The companies have signed an exclusive license agreement for Takedas development, manufacturing and commercialization of NVX-CoV2373, Novavax COVID-19 vaccine candidate, in Japan.